Download Our Paper
Download our white paper on how to overcome the biggest obstacles in conducting an Atopic Dermatitis clinical trial
Click on the image to the left to begin your download
In light of the impact Atopic Dermatitis has on individuals and society as a whole, continued research and awareness efforts are crucial to improve diagnosis, treatment, and ultimately, patients' quality of life.
The development of clinical trial protocols that meet FDA approval standards is crucial for the success of new AD treatments.
If you have any questions, please feel free to contact us directly.
Atopic Dermatitis Clinical Trials
Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin disease marked by itchy and inflamed skin. It is one of the most common skin diseases, especially among children, but it can persist into adulthood or start at an older age.
Over the decades, research has evolved from viewing AD merely as an allergic condition to understanding its complex pathophysiology involving epidermal barrier dysfunction, immune dysregulation, and environmental and psychological factors.
This shift has been pivotal in shaping current therapeutic strategies which aim to restore barrier function, reduce immune dysregulation, and manage environmental and lifestyle factors.
iNGENū's team of experienced researchers and clinicians specializes in designing and conducting innovative studies. Leveraging enhanced trial design and comprehensive patient-centric strategies, we are committed to accelerating the development of new treatments for Atopic Dermatitis.
Atopic Dermatitis affects approx
15-20%
of children and 1-3% of adults globally
Around
90%
of cases are diagnosed before the age of 5
The annual economic burden of atopic dermatitis in the U.S. is estimated to exceed
$5b
Our clinical team has over
120
years of combined clinical trial experience
Understand the iNGENū CRO difference
Request a Proposal
- Book a Discovery Call with one of our Advisors by completing the form below
- We will put forward a proposal and strategy within 5 business days